Grupo de investigación en epidemiología de las enfermedades crónicas de alta prevalencia en España
Pfizer (United States)
Nueva York, Estados UnidosPublikationen in Zusammenarbeit mit Forschern von Pfizer (United States) (9)
2011
-
Inappropriate overuse of inhaled corticosteroids for COPD patients: Impact on health costs and health status
Lung, Vol. 189, Núm. 3, pp. 199-206
-
Risk factors for asthma onset between the ages of 12 and 40. results of the FENASMA study
Archivos de Bronconeumologia, Vol. 47, Núm. 9, pp. 433-440
2010
-
The influence of heart disease on characteristics, quality of life, use of health resources, and costs of COPD in primary care settings
BMC Cardiovascular Disorders, Vol. 10
2009
-
Characteristics of chronic obstructive pulmonary disease in Spain from a gender perspective
BMC Pulmonary Medicine, Vol. 9
-
Health, treatment and health care resources consumption profile among Spanish adults with diabetes and chronic obstructive pulmonary disease
Primary Care Diabetes, Vol. 3, Núm. 3, pp. 141-148
2008
-
Determinants and predictors of the cost of COPD in primary care: A Spanish perspective
International Journal of COPD, Vol. 3, Núm. 4, pp. 701-712
2003
-
Safety and effectiveness of replacing standard doxazosin with doxazosin in the gastrointestinal therapeutic system (GITS) formulation in elderly hypertensive patients
International Journal of Clinical Practice, Vol. 57, Núm. 4, pp. 267-272
2002
2000
-
Drug surveillance study of amlodipine in patients with hypertension not controlled with drug therapy: NORCON study
Current Therapeutic Research - Clinical and Experimental, Vol. 61, Núm. 12, pp. 863-870